Business
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of updated CRB-701 data in HNSCC and cervical cancer at ASCO 2026Completed enrollment in 16-week study CANYON-1 study (n=240) of CRB-913 for the treatment of obesity with topline data on track to report this summer NORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NA
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Corbus Pharmaceuticals Holdings, Inc.","displaySize":"","headline":null,"caption":"Corbus Pharmaceuticals Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s.OOMjw5vP2R8k_UsUT7JA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18","width":300,"height":169},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/s.OOMjw5vP2R8k_UsUT7JA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18","width":300,"height":169}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced presentation of updated CRB-701 data in HNSCC and cervical cancer at ASCO 2026","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed enrollment in 16-week study CANYON-1 study (n=240) of CRB-913 for the treatment of obesity with topline data on track to report this summer ","length":149,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":409,"olType":false},{"type":"text","content":"NORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 first quarter ended March 31, 2026.","length":340,"tagName":"p"},{"type":"text","content":""We’ve continued to build strong momentum with CRB-701 and CRB-913, setting the stage for rapidly approaching inflection points for both the oncology and obesity programs,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.","length":237,"tagName":"p"},{"type":"text","content":"“Having reached broad alignment with the FDA, we’re on track to start a registrational study for CRB-701 in second-line HNSCC this summer. We’ll report updated data at ASCO 2026 that will provide clear ...